Asthma Clinical Trial
Official title:
Measuring the Prevalence of Nocturnal Cough in Asthmatics by Means of Smartphone-enabled Acoustic Recording and Evaluating the Potential of Nocturnal Cough Rate as a Prognostic Marker for Asthma Control: An Observational Two-Stage Study
The purpose of the study is to explore the value which cough rate might provide for asthma
self-management. In this study, the focus will be specifically on nocturnal cough rate. The
plan is to use a longitudinal study design, in order to investigate to which extent trends in
the nocturnal cough rates might have meaningful implications for future asthma control and
asthma exacerbations of patients. The incidence of nocturnal cough in asthmatics will be
described and visualized over the course of one month in the first stage of the study.
Additionally, the aim will be to identify and model trends in nocturnal cough rates.
Measuring cough is very time-consuming. Currently, there are no cough frequency monitors
available, which measure cough rates in a fully automated and unobtrusive way. Consequently,
manual labeling of cough based on video or sound recordings is still considered to be the
gold standard for measuring cough rates by medical guidelines. Recently, a machine learning
algorithm was successfully designed to automatically detect cough in a proof of concept
study. This machine learning algorithm will be further developed in order to provide robust
results in the field. The focus of this study will be the cough during the night time due to
the limited interfering noise, which greatly facilitates manual labeling and enables a more
reliable detection rate of the machine learning algorithm.
Apart from developing a machine learning algorithm for cough detection, data will be gathered
for the assessment of patient's sleep quality based on data obtained from smartphone's
sensors.
Asthma, a chronic respiratory disease, belongs to the most prevalent chronic conditions. In
Switzerland, 7-15% of all children and 6-7% of all adults suffer from it. Common symptoms are
breathlessness, coughing and wheezing. The symptoms often get worse at night and often cause
awakenings. Cough is a particularly important symptom in asthma because it predicts asthma
severity, indicates a worse prognosis and is perceived to be a troublesome symptom.
Additionally, asthma is the leading cause for chronic cough, responsible for 24-29% of cases.
However, little is known about the utility of cough tracking for self-monitoring purposes in
asthmatics. A first cross-sectional study has indicated that the cough rate during both day
and night might be a valid marker for asthma control, rendering it a potentially useful
parameter for self-monitoring. Unfortunately, due to considerable variance of cough rates
within each category of asthma control (i.e. uncontrolled, partially controlled and
controlled asthma), the statistically significant relationship between cough rate and asthma
control might not be clinically meaningful. Additionally, due to the cross-sectional design
of existing studies, it remains unclear whether the cough rate might have any prognostic
value for predicting future asthma control.
Therefore, the purpose of this study is to explore the value which cough rate might provide
for asthma self-management in more detail. In This study, the focus will be put specifically
on nocturnal cough rate due to the technical reasons. In general, the plan of this study is
as follows: With a longitudinal study design, it is possible to investigate to which extent
trends in the nocturnal cough rates might have meaningful implications for future asthma
control and asthma exacerbations of patients. However, in order to analyze the predictive
value of trends in nocturnal cough rate, the symptom has to persist over multiple nights.
There is no research available on the prevalence of nocturnal cough in asthmatics over
multiple nights. Therefore, the incidence of nocturnal cough in asthmatics will be described
and visualized over the course of one month in the first stage of our study. Additionally,
the aim will be to identify and model trends in nocturnal cough rates.
Measuring cough is very time-consuming. Currently, there are no cough frequency monitors
available, which measure cough rates in a fully automated and unobtrusive way. Consequently,
manual labeling of cough based on video or sound recordings is still considered to be the
gold standard for measuring cough rates by medical guidelines. Nevertheless, a machine
learning algorithm has been successfully designed to automatically detect cough in a proof of
concept study. Despite using only very limited data for algorithm development (80 coughs from
5 healthy subjects), the accuracy reached 83%. However, the data were gathered in a
laboratory setting, which limits the generalizability of the results and thus applicability
in practice. Therefore, the aim is to develop a machine learning algorithm which is also
capable to provide robust results in the field. This study will focus on cough during the
night time due to the limited interfering noise, which greatly facilitates manual labeling
and enables a more reliable detection rate of the machine learning algorithm. It is important
to point out that the analysis of nocturnal cough prevalence described above will not be
based on cough detected by an algorithm, but on the manually labeled coughs in the audio
track recorded during the night by a study smartphone, which will be provided to subjects for
the course of the study.
Apart from developing a machine learning algorithm for cough detection, data will be gathered
for an algorithm assessing patient's sleep quality. For this purpose, sleep quality will be
predicted based on data obtained from the smartphone's sensors.
After concluding the first study stage, the prevalence of nocturnal cough in the study will
determine whether further analyses of the recorded data will be needed and thereby initiate
the second stage of the study. If nocturnal cough does not occur more frequently than could
be explained by chance alone, no additional analysis will be conducted implying that the
conclusion of the first stage and the end of the project. However, given a sufficient
prevalence of nocturnal cough in the first stage (i.e. nocturnal cough prevalence differs
from zero with statistical significance); the second stage of the study will focus on the
value of nocturnal cough as a prognostic marker for asthma control. The considerable variance
within categories of asthma control shown in suggests that the relationship between nocturnal
cough rate and asthma control might be moderated by other variables. Prior research has
demonstrated that sleep quality is associated with asthma control and quality of life: Even
if accounted for concomitant diseases (e.g. gastroesophageal reflux disease and obstructive
sleep apnea), poorer sleep quality is associated with worse asthma control and quality of
life. One reason for the association between sleep quality and asthma control might be that
nocturnal asthma symptoms frequently cause awakenings. Considering the importance of sleep
quality for asthma control, the (predictive) value of the nocturnal cough rate and its
influence on sleep quality will be explored.
In summary, the following asthma-related research question will be explored within each stage
of this study: (1) what is the prevalence of nocturnal cough in asthmatics over the course of
one month? (2) Is nocturnal cough, accounted for sleep quality, a valid prognostic marker for
asthma control? Additionally, the study addresses two technical objectives: gather data to
develop two machine learning algorithms, which are able to detect nocturnal cough and sleep
quality fully automated by means of a smartphone in real-life conditions.
Answering these research questions results in multiple contributions: in terms of
asthma-related questions, the hope will be to provide context on the symptom of nocturnal
cough in order to increase interpretability of cough rates and to successfully replicate and
expand the findings of, which would support the validity of nocturnal cough as a (prognostic)
marker for asthma control. In terms of technical objectives, the hope will be to provide a
proof of concept that smartphones are suitable devices for sensing asthma symptoms in an
automated fashion under real-life conditions.
The expected results could enable a novel therapeutic option, namely fully automated
tele-monitoring of asthmatics. Using the smartphone of a patient, an unobtrusive early
warning system for asthma worsening/exacerbations could be envisioned. Such an system could
lower the burden of asthma for both the individual patient (e.g. higher quality of life and
asthma control by identifying windows of opportunity, in which patients can change their
medication according to their asthma action plan to prevent asthma worsening and
exacerbations) as well as the healthcare system (i.e. cost savings due to reduced
hospitalizations and emergency room visits). Considering the wide spread availability of
smartphones, such a novel therapeutic option might enable large scale and cost-efficient
asthma tele-monitoring. Prior research has indicated the need for such a novel therapeutic
option: the majority of asthmatics suffers from uncontrolled asthma. Half of asthmatics are
not able to assess their symptom severity properly and would thus benefit from an early
warning system. Additionally, automated systems seem to have a higher long term engagement
compared to traditional interventions, making them particularly suitable for early warning
systems in chronic diseases. Furthermore, tele-monitoring of symptoms could provide
physicians with valuable insights regarding a patient's asthma symptoms between visits. In
summary, an automated early warning system might help patients register asthma worsening
earlier and inform their physicians in time, so that adverse health consequences can be
prevented.
The planned study falls into the risk category of health related personal data collection
with only minimal risk and burdens. It is a prospective observational study, no intervention
will be administered. Only a slight and temporary impact on the participant's health can be
expected, if at all.
Throughout the study, a patient's asthma symptoms will be monitored unobtrusively using the
smartphone; thus, minimal risk and burdens are ensured. Between both doctoral visits at the
beginning and end of the study, all control questions and questionnaires will be administered
via smartphones that we will provide for this study. Thus, the burden should be minimal for
patients as their daily routine will not be disrupted.
No invasive procedure will be conducted in the two doctoral visits. The medical examination
follows the standard protocol for asthma. Additionally, patients will be reimbursed for any
inconveniences encountered during the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|